EQ logo

Equillium (EQ) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 October 2018

Indexes:

Not included

Description:

Equillium is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. They aim to improve patient outcomes by targeting specific immune pathways, using advanced science to create effective treatments for conditions like lupus and multiple sclerosis.

Key Details

Price

$0.79

Annual Revenue

$36.08 M(+128.97% YoY)

Annual EPS

-$0.38(+79.46% YoY)

Annual ROE

-48.92%

Beta

1.99

Events Calendar

Earnings

Next earnings date:

Mar 25, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 25, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

01 Nov '24 Jones Trading
Hold
19 Aug '24 HC Wainwright & Co.
Buy
05 June '24 HC Wainwright & Co.
Buy
17 May '24 HC Wainwright & Co.
Buy
02 Apr '24 HC Wainwright & Co.
Buy
26 Dec '23 HC Wainwright & Co.
Buy
13 Nov '23 HC Wainwright & Co.
Buy
14 Aug '23 HC Wainwright & Co.
Buy
14 Aug '23 Cantor Fitzgerald
Overweight
15 May '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
EQ
zacks.com08 August 2024

Equillium, Inc. (EQ) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.10 per share a year ago.

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
EQ
businesswire.com18 July 2024

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 million from the end of the first quarter of 2024. The increase is primarily the result of receiving a tax credit of.

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
EQ
Zacks Investment Research25 March 2024

Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago.

5 Top-Ranked Stocks That Have More Than Doubled Year to Date
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
EQ
Zacks Investment Research23 February 2024

Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.

Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
EQ
Zacks Investment Research09 August 2023

Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.

FAQ

  • What is the primary business of Equillium?
  • What is the ticker symbol for Equillium?
  • Does Equillium pay dividends?
  • What sector is Equillium in?
  • What industry is Equillium in?
  • What country is Equillium based in?
  • When did Equillium go public?
  • Is Equillium in the S&P 500?
  • Is Equillium in the NASDAQ 100?
  • Is Equillium in the Dow Jones?
  • When was Equillium's last earnings report?
  • When does Equillium report earnings?
  • Should I buy Equillium stock now?

What is the primary business of Equillium?

Equillium is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. They aim to improve patient outcomes by targeting specific immune pathways, using advanced science to create effective treatments for conditions like lupus and multiple sclerosis.

What is the ticker symbol for Equillium?

The ticker symbol for Equillium is NASDAQ:EQ

Does Equillium pay dividends?

No, Equillium does not pay dividends

What sector is Equillium in?

Equillium is in the Healthcare sector

What industry is Equillium in?

Equillium is in the Biotechnology industry

What country is Equillium based in?

Equillium is headquartered in United States

When did Equillium go public?

Equillium's initial public offering (IPO) was on 12 October 2018

Is Equillium in the S&P 500?

No, Equillium is not included in the S&P 500 index

Is Equillium in the NASDAQ 100?

No, Equillium is not included in the NASDAQ 100 index

Is Equillium in the Dow Jones?

No, Equillium is not included in the Dow Jones index

When was Equillium's last earnings report?

Equillium's most recent earnings report was on 13 November 2024

When does Equillium report earnings?

The next expected earnings date for Equillium is 25 March 2025

Should I buy Equillium stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions